Search research articles
Contact Us
Filters
Showing results (81-90 of 164) with videos related to
Page
of 17
Sort By:
Cancer Chemotherapy and Pharmacology
|
January 23, 2014
Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors
Edward Sausville, Patricia Lorusso, Michael Carducci, et al.
Investigational New Drugs
|
August 4, 2010
A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies
Elisabeth I Heath, Patricia Lorusso, Suresh S Ramalingam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 11, 2012
Pharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel antiangiogenesis agent, in two phase I trials in patients with advanced solid tumors
Yan Xin, Jessica Li, Jenny Wu, et al.
Clinical Pharmacology in Drug Development
|
May 26, 2018
Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors
Geoffrey I Shapiro, Rebecca S Kristeleit, Howard A Burris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 16, 2014
Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors
Paul Haluska, Michael Menefee, Elizabeth R Plimack, et al.
JCO Precision Oncology
|
February 27, 2024
Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors
Yiduo Hu, Azeet Narayan, Yunshan Xu, et al.
Cancer Chemotherapy and Pharmacology
|
June 18, 2016
Evaluation of the effect of necitumumab on the corrected QT interval in patients with advanced solid tumors
David C Smith, John Powderly, James J Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2004
Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study
Emiliano Calvo, Anthony W Tolcher, Lisa A Hammond, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2012
A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine
Ian E Krop, Patricia LoRusso, Kathy D Miller, et al.
Investigational New Drugs
|
August 2, 2020
A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors
Geoffrey I Shapiro, Patricia LoRusso, Daniel C Cho, et al.
Page
of 17
Search research articles
Search
Showing results (81-90 of 164) with videos related to
Sort By:
Page
of 17
Cancer Chemotherapy and Pharmacology
|
January 23, 2014
Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors
Edward Sausville, Patricia Lorusso, Michael Carducci, et al.
Investigational New Drugs
|
August 4, 2010
A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies
Elisabeth I Heath, Patricia Lorusso, Suresh S Ramalingam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 11, 2012
Pharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel antiangiogenesis agent, in two phase I trials in patients with advanced solid tumors
Yan Xin, Jessica Li, Jenny Wu, et al.
Clinical Pharmacology in Drug Development
|
May 26, 2018
Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors
Geoffrey I Shapiro, Rebecca S Kristeleit, Howard A Burris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 16, 2014
Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors
Paul Haluska, Michael Menefee, Elizabeth R Plimack, et al.
JCO Precision Oncology
|
February 27, 2024
Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors
Yiduo Hu, Azeet Narayan, Yunshan Xu, et al.
Cancer Chemotherapy and Pharmacology
|
June 18, 2016
Evaluation of the effect of necitumumab on the corrected QT interval in patients with advanced solid tumors
David C Smith, John Powderly, James J Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2004
Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study
Emiliano Calvo, Anthony W Tolcher, Lisa A Hammond, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2012
A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine
Ian E Krop, Patricia LoRusso, Kathy D Miller, et al.
Investigational New Drugs
|
August 2, 2020
A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors
Geoffrey I Shapiro, Patricia LoRusso, Daniel C Cho, et al.
Page
of 17